In the present paper we address the question if fluorescence diagnostics can be used to monitor and possibly predict the outcome of Photodynamic Therapy (PDT) using the tumor seeking agents Photofrmn and camino1evulinic acid (ALA). The degree of selective uptake may 'ary from patient to patient and it would be interesting to use the drug-related fluorescence signal as a tool to tailor the treatment strategy.
Introduction
Photodynamical therapy (PDT) is a malignant tumor treatment modality relying on a selective transfer of triplet to singlet oxygen mediated by a laser excited sensitizing drug. The drug is normally injected intravenously and is selectively retained in malignant tissue. Thus, a selective necrosis of cancer lesions can be achieved. Laser-induced fluorescence (LIF) can be utilized to localize the tumor based on specific drug fluorescence and native chromophore fluorescence. It has been found that the prime mechanism for tumor destruction is damage to the vessels supplying the tumor The only agent presently in more common clinical use is a haematoporhyrin derivative, available under the trade mark of Photofrin.
The drug is normally injected 48 hours prior to the laser treatment which follows at a wavelength of 630 nm. Good clinical results have been obtained by different groups for a variety of malignant tumors [1, 2] The only side effect of PDT using Photofnn is a skin sensitization for about 4 weeks calling for the patients to stay out of strong ambient light during such a time period The first PDT treatments in Scandinavia were performed by our group in 1987 using a laboratory laser set-up consisting of an argonion laser pumping a dye laser [3, 4] . One of the early patients treated for multiple basal cell carcinoma now has a follow-up time of more than four years showing no recurrences in the treated areas.
Recently, a different PDT procedure for treating . superficial tumors has been applied by Kennedy et al [5] In this case -aminolevulinic acid (ALA) prepared in 20% concentration in an oil-water base is topically applied on the lesions 3-6 hours prior to the treatment. The small ALA molecules pass the cell walls of the tumor cells and are intra-cellularly transformed to protoporphyrin following the normal heme cycle in the mitochondria [6] Following laser irradiation at 630 nm the photodynamic action is initiated Due to the different nature of administration no problems due to photosensitization to ambient light occur.
In the present paper we report case studies of PDT in three patients with multiple lesions of basal cell carcinoma or metastatic breast cancer Conventional PDT using
Photofrin as well as PDT using topical application of ALA was applied A new treatment laser based on a high repetition rate Nd YAG laser frequency-doubled to 532 nm to pump a dye laser was employed Extensive laser-induced fluorescence (LIF) measurements on tumors and normal tissue were performed before and after PDT using a fluorosensor, described in [7] The main purpose of the present study is to relate the LIF results to the treatment outcome and to study the bleaching • of the sensitizer as studied by LIF to infer the deposited dose of light. The bleaching or photodegradation of the sensitizer molecules is manifested in a reduction in the fluorescence light intensity accompanied by the appearance of a further characteristic fluorescence peak in the red spectral region Utilization of the drug bleaching has been proposed for achieving a deeper treatment effect in the irradiated tissue [8] Because of the stronger photodegradation of the agent in the superficial tissue layers subject to the strongest light intensity, the upper layer is protected from overtreatment, provided that the correct initial drug concentration is chosen Further irradiation will continue the treatment in the deeper layers with continuing bleaching.
Materials and Methods
Below three case studies will be presented. In the LIF investigations and the PDT treatment we used the agents and the equipment as follows.
Drugs -For intravenous injection we used Photofrin (Quadra Logic Technologies, Vancouver, Canada), Lot # B90-0020. The drug was injected at a concentration of 1 or 2 mg/kg body weight For topical application we used -aminolevulinic acid hydro chloride (ALA) (Porphyrin Products Inc , Logan, Utah), catalogue # A167, Lot # 072791 The powder (0 5 g) was dissolved in 0 5 g sterile water and was then mixed with 1 5 g Essex cream (Schering Corp, Kenilworth, New Jersey), to yield a 20 % ALA cream The cream was applied to the lesions and their close surroundings and was kept in place for a time period of 6 hours using an occlusion cover.
Laser equipment for PDT In the present treatments we used a Technomed Multilase 2500 Nd:YAG laser system operating on its second harmonic (532 nm) to pump a Technomed Dye 600 laser tuned to 630 nm. The red radiation was conducted through a 400 im quartz fibre. The polished end face of the fibre was imaged using a 40 times magnification microscope objective onto the lesion in a slightly diverging beam. By adjusting the distance between the microscope objective and the lesion a "top hat" uniform intensity dist:ribution of the desired diameter could be obtained; Typically, a total energy of about 1 W was delivered onto the targpt resulting in irradiation times of typically 15 minutes for achieving a dose of 50 J/cm in a circle of 5 cm diameter. Normally, a margin of 5 mm was allowed in the treatment of the tumors. The power of the projected beam was measured by a calibrated large-area power meter before and after a tumor irradiation.
.
Laser fluorosensor for LIF -For recording tissue fluorescence spectra we used the clinical fluorosensor (lesCribed in [7] . This equipment uses a single quartz fibre of Normally, the signal from 100 laser pulses were averaged during a period of 10
seconds. The signals were spectrally corrected using a calibrated standard lamp. Case 3. A 55 year old woman was treated for local recurrences of breast cancer on the thoracic wall. Three different treatment procedures were performed. In the two initial procedures intravenously injected Photofrin (1 mg/kg b.w.) was used, whereas the last one was performed fter topically applying ALA. All procedures were performed with a light dose of 50 J/cm in a single light administration procedure.
During the two first procedures three areas ranging in diameter from 540 cm were treated on the thoracic wail and in the axilla. Immediately after the treatment a slight oedema appeared in the treated areas. Six hours later the oedema had disappeared and a halo was formed with its outer border corresponding with the border line of the laser light. The tumors started to leak clear liquid from day two after the treatment and continued for about eight days. Thereafter the tumors were covered with a black necrotic crust which stayed for about 6 weeks on the two smaller lesions and 12 weeks on the larger area. When the crusts fell off the granulation and part of the reepitalization was already finished. Three months after the PDT fine needle cytology was performed on the healed lesions and no vital tumor cells could be a tumor and for normal skin are given to the lower right. In Fig. 4 the same set of scans are shown for a basal cell carcinoma treated with ALA (case 2). Also in this case the bleaching was prominent. In the scan of A/B an excellent tumor demarcation can be seen. This is also clear in the two spectra shown in this figure. It should be noted, that the points representing normal areas were exposed to the same amount of ALA cream as the tumor. Nevertheless, no conversion to protoporphyrin has occurred in these areas. For case 3, two sets of scans are shown, one for Photofrin (Fig. 5a ) and one with ALA sensitization (Fig. 5b) . Interestingly, only the tumors exposed to ALA showed strong bleaching. Also the tumor demarcation was better for the case with ALA. TUMOR.
[Photofrin] IEEOIEIIJ high as shown in Ref. [5] and confirmed in the present work. The treatment procedure does not include any side effects and can easily be performed on an out-patient basis.
In cases with local recurrences of breast cancer, PDT following intravenous administration of Photofrin is a promising complementary treatment modality, as the patients often have gone through many other treatment modalities including full radiation therapy and nothing else can be offered. PDT2 utilizing ALA in locally recurrent breast cancer may require light doses of 100 J/cm and also longer time for the ALA to penetrate the skin more efficiently as the local metastases of breast cancer are located subcutaneously as well as cutaneously. With optimal laser light dosimetry and efficient ALA administration PDT following topical administration sensitizer may also be valuable for this kind of skin tumors.
When porphyrin-containing tissue is irradiated to achieve photodynamic action, a fluorescence peak at about 670 nm, not detectable prior to irradiation, will normally Yamashita et In view of Fig. 2 In principle, it should be possible to obtain iso-dose images using the multi-color imaging technique developed in our group [11, 12] . Here, up to four images can be that we . did not observe any employing Photofrin application J/cm2 was applied to the irradiated areas and good tumor response was observed. The absence of bleaching for some porphyrin fractions has been observed in vitro [13] . It may be that the biological surrounding influences the porphyrin molecules and their response to the laser light. The pH value may play an important role. The tumor areas in which we could not observe any bleaching were low differentiated cancer with very fast growth and probably low pH value and minimal oxygen content. When employing ALA for the same kind of tumor we observed a substantial bleaching in the fluorescence but a very weak tumor effect. I may be that the ALA molecules entering the cancer cells via the heme cycle find binding sites where they are not phototoxically active although influenced by the light. The strongly fluorescent molecules formed may not be able to transform triplet oxygen into singlet oxygen to induce cell death. ALA. in the treatment of local recurrences of breast cancer has to be investigated further.
The light dosimetry and the drug application must be improved. The possibility for the ALA creme to penetrate more efficiently may be improved by stripping off the covering stratum corneum. Another possibility would be to repeat the treatment procedure several times to penetrate deeper into the subcutaneous tissue.
The present work indicates, that fluorescence monitoring in interplay with PDT can provide information of value for optimizing the laser treatment procedure and the light dose applied. If these phenomena are well understood, fluorescence measurements should help considerably in order to avoid under-as well as overtreatment. Obviously, it is necessary to perform careful studies for different types of tumors to gain the insight needed to take full advantage of the diagnostic information provided by a clinical fluorosensor.
